Moderna (MRNA) shares fell more than 19% in premarket activity Monday after the company said it now expects 2025 revenue to be between $1.5 billion and $2.5 billion, down from the previous range of $2.5 billion to $3.5 billion.
Analysts surveyed by FactSet expect $2.92 billion.
The drugmaker said it is accelerating its cost efficiency and prioritization programs, with projected cash cost reductions of $1 billion in 2025.
The company said it expects to end 2025 with cash and investments of about $6 billion.
Moderna will report its Q4 financial results on Feb. 14.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.